Paclitaxel Monitoring in Patients with Solid Tumors

Inclusion Criteria

• Individuals receiving treatment at the Wake Forest Comprehensive Cancer Center who are anticipated to receive paclitaxel for curative or palliative intent, with or without surgery and/or radiation (i.e. neoadjuvant, adjuvant, or in the setting of recurrent or metastatic disease) as per decision with their medical oncologist for the following malignancies and dosing regimens:
• Invasive breast cancer (any HER2 and estrogen receptor [ER]/progesterone receptor [PR] status) * Patients considered for curative or palliative chemotherapy with paclitaxel 80-175 mg/m^2 with or without doxorubicin, cyclophosphamide, carboplatin, trastuzumab, bevacizumab, or pertuzumab
• Cervical cancer * Patients considered for curative or palliative chemotherapy with paclitaxel 135-175 mg/m^2 with or without cisplatin, carboplatin, topotecan, or bevacizumab
• Non-small cell lung cancer * Patients considered for curative or palliative chemotherapy with paclitaxel 45-200 mg/m^2 with or without carboplatin, cisplatin, bevacizumab, atezolizumab, or pembrolizumab
• Ovarian cancer * Patients considered for curative or palliative chemotherapy with paclitaxel 60-175 mg/m^2 with or without carboplatin, cisplatin, ifosfamide, gemcitabine, pazopanib, or bevacizumab
• Uterine neoplasms * Patients considered for curative or palliative chemotherapy with paclitaxel 135-175 mg/m^2 with or without carboplatin, cisplatin, doxorubicin, ifosfamide, bevacizumab, or trastuzumab
• Vulvar cancer (squamous cell carcinoma) * Patients considered for curative or palliative chemotherapy with paclitaxel 60-175 mg/m^2 with or without cisplatin, carboplatin, or bevacizumab
• Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document
• Patients with prior radiation treatment or surgery will not be disqualified from enrollment into the study, unless the aforementioned interventions resulted in peripheral neuropathy as a complication

Exclusion Criteria

• Prior treatment with PTX, for any duration or indication
• Prior treatment with neurotoxic chemotherapy including any taxane, vinca alkaloid, platinum-containing agent, bortezomib, or thalidomide that has resulted in clinical symptoms of persistent, Common Terminology Criteria for Adverse Events (CTCAE) grade II or higher peripheral neuropathy
• Concurrent enrollment in a clinical study of a neuroprotective intervention at the time of study initiation
• Any contraindication to PTX (e.g. history of allergic reaction to paclitaxel or Kolliphor EL)
• Current signs or symptoms of peripheral neuropathy at the time of enrollment, e.g. due to diabetes, human immunodeficiency virus (HIV), or other conditions
• Known personal or family history of hereditary peripheral neuropathy (e.g. Charcot-Marie-Tooth disease)